Compare AbbVie Inc (ABBV) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares MSCI India ETF — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while iShares MSCI India ETF trades at $48.64. The key difference: AbbVie Inc pays a 2.72% dividend while iShares MSCI India ETF pays none, and AbbVie Inc is trading nearer its 52-week high, iShares MSCI India ETF nearer its low. Which is the better fit depends on your goals.
| ABBV | INDA | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $261.07 | $55.69 |
52-Week Low | $184.85 | $45.42 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.78, down 0.78% on the day, with a bullish technical signal from moving averages and strong institutional support. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $2.65 surpassing the $2.59 estimate. Revenue growth is robust, driven by Skyrizi and Rinvoq offsetting Humira declines, though net margins have compressed from 20.38% in 2022 to 6.9% in 2025. Positive news includes phase 2 trial results for ELAHERE in ovarian cancer and sustained dividend payments.
The outlook remains positive with a consensus price target of $266.33 implying ~5% upside, supported by 68% analyst buy ratings. Key risks include patent expirations in the 2030s, margin pressure, and regulatory lawsuits. Cash flow trends show improvement, with 2026 projected net cash flow turning positive to $4.2B, enhancing financial flexibility for growth investments and dividends.
INDA, the iShares MSCI India ETF, trades at $49.88 with a 0.65% daily gain, showing bullish technical momentum with strong moving average signals. The ETF provides exposure to Indian equities, which face mixed sentiment due to AI transition challenges and geopolitical risks, though India's economy grew 7.8% in Q1 2026. Technical indicators show neutral oscillators but overall bullish bias with key support at $49.
The outlook remains cautiously optimistic with India's strong GDP growth offset by sector-specific headwinds. Investment opportunity lies in India's economic expansion and discounted valuation versus S&P 500, while risks include monsoon uncertainties, Middle East tensions affecting inflation, and foreign investor outflows of $26.4 billion in 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
